Hanmi Pharm terminates development of Olita, “We’ll focus efforts on making global new drugs”
Hanmi Pharm(CEO Sae-Chang Kwon & Jong-Soo Woo) decided to terminate development of ‘Olita(generic name: olmutinib),’ a targeted therapy for lung cancer, and announced on the 13th that the company has been in progress to make an agreement with the Ministry of Food and Drug Safety(MFDS) for the det...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.